Immune-Onc Therapeutics Presents IO-202 Phase 1 Data in Patients with ...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: October 2, 2023

ComplyCube Unveils No-ID Age Estimation to Address Growing Global Age-Restriction Regulations • BWX Technologies to Announce Third Quarter 2023 Results on Wednesday, November 1 • Simon® Earns GRESB Green Star • iQor Celebrates Customer Service Week 2023 • Most Women Skipping Annual Mammograms, According to New MedStar Health Survey • Feinstein Institutes’ Ross Prize awardees win 2023 Nobel Prize in Physiology or Medicine • Honouliuli National Historic Site Commemorated with Blessing Event and Plaque Dedication Ceremony • Veteran Tech Exec Sissie Hsiao joins Bumble Inc. Board of Directors • J&J Patent Move Must be First of Many, says AHF • Afya Limited to Report Third Quarter and Nine Months 2023 Financial Results on November 13th • Remedios Varo Exhibition at Art Institute of Chicago Celebrates Hispanic Heritage Through Art • Andreozzi + Foote File Lawsuits as the New Maryland Child Victims Law Takes Effect • Carmen M. Hernández Joins HITN’s Board of Directors • How to Make a Difference This Halloween • Link Logistics Publishes Third Annual ESG Report • Empire State Realty Trust Announces Acquisition of Prime Retail Asset in Williamsburg, Brooklyn, as Part of Capital Recycling Pr • U.S. Postal Service Commemorates Legacy of Ruth Bader Ginsburg • EPA Names Clorox as 2023 Safer Choice Partner of the Year for Advancing Ingredient and Product Safety • Essential Utilities Completes Sale of West Virginia Gas Utility Assets • Global Gaming Women Announces Event Line-up at Global Gaming Expo 2023 including the 13th Annual Kick Up Your Heels Fundraiser

Immune-Onc Therapeutics Presents IO-202 Phase 1 Data in Patients with Relapsed or Refractory AML and CMML at the EHA Annual Meet

PALO ALTO, Calif. , June 08 /Businesswire/ - @ImmuneOnc presents IO-202 Phase 1 data in patients with relapsed or refractory AML and CMML at the EHA annual meeting 2023 and announces @US_FDA #FastTrackDesignation to IO-202 for the treatment of relapsed or refractory CMML.